Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Hypersensitivity Reaction
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Hypersensitivity Reaction or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Hypersensitivity Reaction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Canadian expert consensus: management of hypersensitivityreactions to intravenous iron in adults Canadian expert consensus: management of hypersensitivityreactions to intravenous iron in adults - Lim - - Vox Sanguinis - Wiley Online Library The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
HLA-A*3101 and carbamazepine-induced hypersensitivityreactions in Europeans. Carbamazepine causes various forms of hypersensitivityreactions, ranging from maculopapular exanthema to severe blistering reactions. The HLA-B*1502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations.We performed a genomewide association study (...) ), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).The presence of the HLA-A*3101 allele was associated with carbamazepine-induced hypersensitivityreactions among subjects of Northern European ancestry. The presence of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 3.8%. (Funded by the U.K. Department of Health and others.).
Hypersensitivityreactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. To describe the outcomes of clinical evaluation, skin testing, and vaccine challenge in adolescent schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine introduced in Australian schools in 2007.Retrospective cohort study.Two tertiary paediatric allergy centres in Victoria and South Australia, Australia.35 schoolgirls aged 12 to 18.9 years (...) with suspected hypersensitivityreactions to the quadrivalent human papillomavirus vaccine.Clinical review and skin prick and intradermal testing with the quadrivalent vaccine and subsequent challenge with the vaccine.35 schoolgirls with suspected hypersensitivity to the quadrivalent human papillomavirus vaccine were notified to the specialised immunisation services in 2007, after more than 380 000 doses had been administered in schools. Of these 35 schoolgirls, 25 agreed to further evaluation. Twenty three
Paclitaxel hypersensitivityreactions: assessment of the utility of a test-dose program Paclitaxel hypersensitivityreactions: assessment of the utility of a test-dose program Paclitaxel hypersensitivityreactions: assessment of the utility of a test-dose program Henry A, Charpiat B, Perol M, Vial T, De Saint Hilaire P J, Descotes J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cancer patients prescribed paclitaxel were initially given a test dose before the first and second cycles of paclitaxel chemotherapy, to see whether they experienced hypersensitivityreactions (HSRs). The test dose consisted of a 12 mg dose prepared in 10 mL of normal saline and infused intravenously over 6 minutes. The patients were observed
Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivityreaction. Drug hypersensitivityreactions are common and can be life-threatening. Confirmation of the diagnosis should be rigorous and based on clinical history and a physical examination, possibly followed by skin tests and drug provocation tests.To describe the outcome of drug provocation tests in evaluating patients with histories suggesting drug allergy.Retrospective analysis of clinic case (...) series.The department for drug allergy at a university hospital.898 consecutive patients with suspected immediate drug allergy referred to the clinic between September 1996 and August 2001. Patients with severe skin reactions and those with positive results on skin tests for beta-lactams were excluded.Single-blinded administration of increasing doses of the suspected drug, up to the usual daily dose, under strict hospital surveillance.1372 drug provocation tests were performed using various drugs
Delayed drug hypersensitivityreactions. Immune reactions to small molecular compounds, such as drugs, can cause a variety of diseases involving the skin, liver, kidney, and lungs. In many drug hypersensitivityreactions, drug-specific CD4+ and CD8+ T cells recognize drugs through their alphabeta T-cell receptors in an MHC-dependent way. Drugs stimulate T cells if they act as haptens and bind covalently to peptides or if they have structural features that allow them to interact with certain T (...) reactions through the release of various cytokines (for example, interleukin-5, interferon) and chemokines (such as interleukin-8). Activation of T cells with a particular function seems to lead to a specific clinical picture (for example, bullous or pustular exanthema). Taken together, these data allow delayed hypersensitivityreactions (type IV) to be further subclassified into T-cell reactions, which through the release of certain cytokines and chemokines preferentially activate and recruit monocytes
Genetic variations in HLA-B region and hypersensitivityreactions to abacavir. Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivityreactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p<0 small middle dot0001). However, because of low numbers of women and other ethnic groups (...) enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivityreactions among patients receiving abacavir must remain unchanged.